Clinical Trials | June 14, 2024
USFDA approves expanded age indication for GSK’s RSV vaccine ‘Arexvy’
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
Cresset’s new India site will support the growing demands of Cresset’s APAC customer base
Elegen is the only DNA manufacturer delivering the unique combination of complexity, length and NGS-verified accuracy within days
The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody
Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
The new gummy capabilities include a dedicated R&D lab, an automated production line, and bottle packaging solutions
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
The VitalDose Drug Delivery Platform has been used in patient-centric dose forms in women’s health for over two decades
Subscribe To Our Newsletter & Stay Updated
